Dr Sharon Cohen Featured in CNBC Report on Biogen’s Aducanumab during PBS Business News Hour

Dr Sharon Cohen Featured in CNBC Report on Biogen's Aducanumab during PBS Business News Hour

Thanks to CNBC’s Meg Tirrell for including comments from Toronto Memory Program’s Dr. Sharon Cohen regarding Biogen’s announcement about aducanumab data at the CTAD conference on December 6, 2019. Recording courtesy of public television station KLRU in Austin, Texas.

Latest Tweets

Treatment with Alzheon's oral candidate ALZ-801 lowered levels of a key biomarker for #alzheimersdisease — and led to significant memory ... improvements in people with the neurodegenerative disorder.
https://alzheimersnewstoday.com/news/oral-alz-801-lowers-key-biomarker-trial-may-slow-alzheimers/

What's happening at the forefront of #Alzheimers research? 🧠🔬

In ep. 126 of Eat Move Think, Dr. Lorne Greenspan checks in with our ... clinical dir. of #genetics Jessica Gu and Dr. Sharon Cohen, the medical director at @Toronto_Memory Program.

Listen now: https://eatmovethinkpodcast.com/podcast/ep126-alzheimers-diagnosis-treatment-prevention

Toronto Memory Program

A Headlands Research Company

© 2022 Toronto Memory Program. All rights reserved.